Heart · 2015 · 113 citations · 21 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPulmonologyCardiac MedicationsCardiac PharmacotherapyCardiovascular Drug SafetyClinical TrialsCongenital Heart DiseasePulmonary HypertensionCongenital Heart Disease PathophysiologyCongenital Heart Disease PharmacologyPersistent Pulmonary Hypertension PharmacotherapyPlacebo-controlled Efficacy AssessmentPulmonary Hypertension Due To Congenital Heart DiseasePulmonary Vascular Resistance AssessmentVascular ResistanceWalking Distance Analysis
OBJECTIVE: The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explore the efficacy and safety of riociguat in the subgroup of patients with persistent/recurrent PAH after correction of congenital heart disease (PAH-CHD) from the PATENT studies. METHODS: In PATENT-1, patients received riociguat (maximum 2.5 or 1.5 mg three times daily) or placebo for 12 weeks; efficacy assessments included change from baseline to study end in 6-min walking distance (6MWD; primary), pulmonary vascular resistance (PVR), N-terminal of the prohormone of brain natriuretic peptide (NT-proBNP), WHO functional class (WHO FC) and time to clinical worsening. In PATENT-2, eligible patients from PATENT-1 received long-term riociguat (maximum 2.5 mg three times daily); the primary assessment was safety and tolerability. All PAH-CHD patients had a corrected cardiac defect. RESULTS: In PATENT-1, riociguat increased mean±SD 6MWD from baseline to week 12 by 39±60 m in patients with PAH-CHD versus 0±42 m for placebo. Riociguat also improved several secondary variables versus placebo, including PVR (-250±410 vs -66±632 dyn·s/cm(5)), NT-proBNP (-164±317 vs -46±697 pg/mL) and WHO FC (21%/79%/0% vs 8%/83%/8% improved/stabilised/worsened). One patient experienced clinical worsening (riociguat 1.5 mg group). Riociguat was well tolerated. In PATENT-2, riociguat showed sustained efficacy and tolerability in patients with PAH-CHD at 2 years. CONCLUSIONS: Riociguat was well tolerated in patients with PAH-CHD and improved clinical outcomes including 6MWD, PVR, WHO FC and NT-proBNP. TRIAL REGISTRATION NUMBER: The clinical trials numbers are NCT00810693 for PATENT-1 and NCT00863681 for PATENT-2.
21
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig et al. · New England Journal of Medicine · 2013 · 1.3K citations · Full text
Lifetime Prevalence of Congenital Heart Disease in the General Population From 2000 to 2010
Ariane Marelli, Raluca Ionescu‐Ittu, Andrew S. Mackie et al. · Circulation · 2014 · 1.2K citations
Medicine, Cardiology, Child Health +10
Bosentan Therapy in Patients With Eisenmenger Syndrome
Nazzareno Galiè, Maurice Beghetti, Michael Α. Gatzoulis et al. · Circulation · 2006 · 836 citations · Full text
Medicine, Cardiology, Pharmacology +17
Updated Clinical Classification of Pulmonary Hypertension
2009 · 380 citations · Full text
Medicine, Cardiology, Pediatrics +10